CSPC Pharmaceutical Group (HK:1093) has released an update.
CSPC Pharmaceutical Group Limited has made a notable advancement in the pharmaceutical market with their latest product, Amphotericin B Liposome for Injection, receiving drug registration approval in China. This product, designed to treat systemic fungal infections, febrile neutropenia in suspected fungal infections, and visceral leishmaniasis, also reduces nephrotoxicity and improves therapeutic outcomes due to its innovative liposomal delivery system.
For further insights into HK:1093 stock, check out TipRanks’ Stock Analysis page.
